Publications by authors named "N Panko"

4 Publications

  • Page 1 of 1

COMORBIDITY OF TYPE 1 DIABETES MELLITUS WITH OTHER CHRONIC PATHOLOGY IN CHILDREN.

Georgian Med News 2021 Mar(312):78-82

1V. Karazin Kharkiv National University, School of Medicine; 2SI "Institute of Health of Children and Adolescents of the National Academy of Medical Sciences of Ukraine", Kharkiv, Ukraine.

In this study was to investigate the сoexistence of diabetes mellitus type 1 with other chronic pathology in children and adolescents and their impact on the course of diabetes mellitus type 1 (DM1). The 88 children from 3 to 17 years who had DM1 were observed. The study was conducted by survey with the aim of finding risk factors and associated comorbidties with a questionnaire-based, objective-subjective study. All patients had severe form of T1DM, with suboptimal and poor glycemic control. Comorbid pathologies observed in 71,6±4,8% of childrn included: thyroid pathology - 62,5±5,1%, disorders of the autonomic nervous system - 20,5±4,3%, gastro-pathology - 7,9±2,8%, atopic dermatitis - 6,8±2,6%, arthritis - 6,8±2,6%, bronchial asthma - 4,5±2,2%, allergic rhinitis - 3,4±1,9%, immune-deficient disorder - 2,3±1,5%. Conclusions. 1. The detected comorbid pathology in children with DM1 makes it necessary to collect an anamnesis and examination of children for the purpose of early finding a coexistence of chronic pathology. 2. The risk of development of the thyroid pathology enhances is 7,5 times, allergic pathology is 6,9 times in patients with DM1. 3. Coexistence of type 1 diabetes and other chronic diseases impairs glucose metabolism, impedes effective insulin therapy, and deteriorates diabetes control. 4. This accent the need for the improvement of the monitoring of patient with diabetes mellitus and comorbid pathology for the prognosis of the course and optimization of treatment and rehabilitation measures.
View Article and Find Full Text PDF

Download full-text PDF

Source
March 2021

; LIVER LESION IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS WITH DIFFERENT DURATION OF METHOTREXATE TREATMENT.

Georgian Med News 2020 Jul-Aug(304-305):95-99

1V.N. Karazin Kharkiv National University, Department of Pediatrics No2; Kharkiv, Ukraine.

The aim of the research was to determine liver lesion in patients with Oligoarticular and RF-negative Polyarticular forms of JIA by noninvasive methods depending on duration of Methotrexate treatment. The study included 42 patients with Rheumatoid factor (RF) negative oligo- and polyarticular joints forms of JIA from 3 to 18 years old. They were investigated by measurement of alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), haptoglobin, triglycerides, gamma glutamine transferase (GGT), apolipoprotein-A (Apo-A), a2-macroglobulin, cholesterine levels. The equation for calculating the FibroTest score regression coefficient had been done according U.S. patent 6.631.330. Student -Fisher Test, Mann - Whitney U-test were used for the statistical processing. In spite of MTX treatment progression of JIA was determined according assessment of joints functional class and radiological stage (p<0.05). Increased level of ALAT was prominent (40%) in children taken MTX for 1-5 years in comparison with other studied patients (p<0.05). 17 % of children who took MTX longer than 5 years had increased GGT content. Metabolic liver function was not changed because levels of Apo-A, haptoglobin, total bilirubin, cholesterine were within normal limits due to all stages of MTX taking. The increased level of a2-macroglobulin as a predictor of liver fibrosis was determined in all studying groups with the average frequency 36 % and it did not correspond to the duration of MTX treatment. According FibroTest score regression 14% of patients had liver fibrosis F1, which did not depend on duration of MTX treatment. According to our findings, patients using MTX for JIA management had joint damage progresses despite usage of MTX. Hepatic cytolysis is most frequently appeared within 15 years of MTX taking. Risk of liver fibrosis does not depend on duration of MTX treatment.
View Article and Find Full Text PDF

Download full-text PDF

Source
September 2020

HIV Infection Is Not a Contraindication to Laparoscopic Sleeve Gastrectomy for Morbid Obesity.

Obes Surg 2018 Feb;28(2):464-468

Presence Saint Joseph Hospital, Chicago, IL, USA.

Background: The efficacy of antiretroviral therapy has made HIV a chronic condition. The prevalence of obesity in HIV positive patients has subsequently risen and is present in 6-34% of men and 21-30% of women (Keithley et al. J Assoc Nurses AIDS Care 20(4):260-74, 2009). Sleeve gastrectomy is a safe and effective procedure for weight loss in the general population, but having HIV may bring hesitation to performing bariatric surgery for some practitioners.

Objectives: The aim of this study is to evaluate the safety and efficacy of laparoscopic sleeve gastrectomy (LSG) in patients with HIV.

Methods: A retrospective analysis of prospectively collected data of patients with HIV who underwent LSG at a community hospital by a single surgeon was performed. Nine patients with HIV underwent LSG. Primary outcomes include weight loss at 6 and 12 months and postoperative CD4 count and viral load. Secondary outcomes include alteration to antiretroviral therapy (ART).

Results: Our patients had a mean BMI of 46 (range 35-66) and were all well controlled on ART preoperatively. Mean weight loss at 12 months was 40 kg (range 21-55), with mean excess body weight loss 69% (range 42-112). There were no significant changes in CD4 counts, and all patients continued to have undetectable viral loads at 1 year postoperatively. One patient had a change in ART, which was unrelated to bariatric surgery. There were no complications in our patient group.

Conclusion: This is the largest series to date evaluating sleeve gastrectomy in HIV-positive patients and further supports the safety and efficacy of sleeve gastrectomy in this patient population.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11695-017-2865-5DOI Listing
February 2018

Invasive Ductal Carcinoma within a Benign Phyllodes Tumor.

Am J Case Rep 2017 Jul 20;18:813-816. Epub 2017 Jul 20.

Department of Surgery, Presence Saint Joseph Hospital, Chicago, IL, USA.

BACKGROUND Phyllodes tumor (PT) is a rare neoplasm of the breast. Concomitant PT with invasive ductal carcinoma (IDC) is an even rarer occurrence. When ductal carcinoma in situ (DCIS) or IDC are detected within the specimen, the management changes from wide local excision to further staging work-up, including sentinel node biopsy and radiation. CASE REPORT We report the case of a 70-year-old presented with right breast mass whose pathology showed benign PT with concomitant IDC and DCIS. The patient elected for a wide excision of the mass with sentinel lymph node biopsy, which did not show any involvement. The patient was started on appropriate therapy. She is currently doing well. CONCLUSIONS This case highlights the importance of wide local excision for PT as well as prudent histologic examination to rule out other malignant components, as the presence of IDC distinctly changes management.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530903PMC
http://dx.doi.org/10.12659/ajcr.903774DOI Listing
July 2017
-->